Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and tolerability of the combination of
epirubicin, oxaliplatin and 5-day continuous infusional 5-fluorouracil (EOF5 regimen) in
patients with unresectable advanced or metastatic gastric cancer (A/MGC). Since Mar 2011, two
addition second endpoints was added to the trial, one was to compare the consistence of two
types of PET Scan evaluation with routine CT Scan evaluation, the other was to search for
predictor factors of clinical results ( ORR,PFS and OS) with Pharmacogenomics methods. This
modification was approved by the Ethic Committee of Fudan University Cancer Hospital, and the
approval number was IRB50-15-1101A.